Immuron Ltd Cash Flow Conversion Efficiency
Immuron Ltd cash flow conversion efficiency. Based on the latest financial reports, Immuron Ltd (IMC) has a cash flow conversion efficiency ratio of -0.189x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.48 Million ≈ $-1.75 Million USD) by net assets (AU$13.08 Million ≈ $9.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immuron Ltd (2001–2025)
Cash flow conversion efficiency of Immuron Ltd from 2001 to 2025. This chart illustrates how Immuron Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Immuron Ltd stock price today for real-time trading data and today's change.
Immuron Ltd Cash Flow Conversion Ratio Explained
Immuron Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immuron Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immuron Ltd ranked by their cash flow conversion efficiency. Also see Immuron Ltd (IMC) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Victoria Insurance Tbk PT
JK:VINS
|
-0.039x |
|
BIG Industries Bhd
KLSE:7005
|
-0.028x |
|
Federal International Holdings Bhd
KLSE:8605
|
-0.049x |
|
Checkin.com Group AB
ST:CHECK
|
0.033x |
|
Real Heart
ST:HEART
|
-0.026x |
|
U-BX Technology Ltd.
NASDAQ:UBXG
|
-0.017x |
|
Plascar Participações Industriais S.A
SA:PLAS3
|
-0.023x |
|
LDT Inc
KQ:096870
|
0.027x |
Annual Cash Flow Conversion Efficiency for Immuron Ltd (2001–2025)
The table below shows the annual cash flow conversion efficiency of Immuron Ltd from 2001 to 2025. Review IMC financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$8.07 Million ≈ $5.71 Million |
AU$-6.14 Million ≈ $-4.34 Million |
-0.761x | -64.39% |
| 2024-06-30 | AU$12.71 Million ≈ $8.99 Million |
AU$-5.88 Million ≈ $-4.16 Million |
-0.463x | -264.71% |
| 2023-06-30 | AU$19.62 Million ≈ $13.88 Million |
AU$-2.49 Million ≈ $-1.76 Million |
-0.127x | +6.13% |
| 2022-06-30 | AU$23.18 Million ≈ $16.40 Million |
AU$-3.13 Million ≈ $-2.22 Million |
-0.135x | +14.30% |
| 2021-06-30 | AU$25.90 Million ≈ $18.32 Million |
AU$-4.08 Million ≈ $-2.89 Million |
-0.158x | +71.88% |
| 2020-06-30 | AU$5.64 Million ≈ $3.99 Million |
AU$-3.16 Million ≈ $-2.24 Million |
-0.561x | -129.19% |
| 2019-06-30 | AU$7.35 Million ≈ $5.20 Million |
AU$-1.80 Million ≈ $-1.27 Million |
-0.245x | +41.08% |
| 2018-06-30 | AU$8.44 Million ≈ $5.97 Million |
AU$-3.50 Million ≈ $-2.48 Million |
-0.415x | +61.17% |
| 2017-06-30 | AU$6.57 Million ≈ $4.65 Million |
AU$-7.03 Million ≈ $-4.97 Million |
-1.069x | -2.42% |
| 2016-06-30 | AU$4.94 Million ≈ $3.50 Million |
AU$-5.16 Million ≈ $-3.65 Million |
-1.044x | -66.26% |
| 2015-06-30 | AU$4.81 Million ≈ $3.40 Million |
AU$-3.02 Million ≈ $-2.14 Million |
-0.628x | -60.80% |
| 2014-06-30 | AU$6.79 Million ≈ $4.80 Million |
AU$-2.65 Million ≈ $-1.88 Million |
-0.391x | +97.23% |
| 2013-06-30 | AU$144.99K ≈ $102.59K |
AU$-2.05 Million ≈ $-1.45 Million |
-14.108x | -1074.35% |
| 2012-06-30 | AU$2.05 Million ≈ $1.45 Million |
AU$-2.46 Million ≈ $-1.74 Million |
-1.201x | -5.67% |
| 2011-06-30 | AU$1.73 Million ≈ $1.23 Million |
AU$-1.97 Million ≈ $-1.39 Million |
-1.137x | -69.19% |
| 2010-06-30 | AU$3.36 Million ≈ $2.38 Million |
AU$-2.26 Million ≈ $-1.60 Million |
-0.672x | -105.99% |
| 2009-06-30 | AU$-184.87K ≈ $-130.81K |
AU$-2.07 Million ≈ $-1.47 Million |
11.209x | +699.89% |
| 2008-06-30 | AU$1.11 Million ≈ $785.58K |
AU$-2.07 Million ≈ $-1.47 Million |
-1.868x | -23.80% |
| 2007-06-30 | AU$1.98 Million ≈ $1.40 Million |
AU$-2.99 Million ≈ $-2.12 Million |
-1.509x | -181.71% |
| 2006-06-30 | AU$5.24 Million ≈ $3.71 Million |
AU$-2.81 Million ≈ $-1.99 Million |
-0.536x | -112.46% |
| 2005-06-30 | AU$6.96 Million ≈ $4.93 Million |
AU$-1.76 Million ≈ $-1.24 Million |
-0.252x | +16.78% |
| 2004-06-30 | AU$4.08 Million ≈ $2.89 Million |
AU$-1.24 Million ≈ $-874.24K |
-0.303x | +0.21% |
| 2002-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-1.92 Million ≈ $-1.36 Million |
-0.304x | -36.77% |
| 2001-06-30 | AU$7.48 Million ≈ $5.29 Million |
AU$-1.66 Million ≈ $-1.17 Million |
-0.222x | -- |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more